The market for ophthalmology drugs is growing rapidly, and local eye drug companies are beginning to rise

In recent years, the aging of the population, the widespread use of electronic products, improper use of the eye and other factors, so that the incidence of various types of eye diseases in China is on the rise, eye infections, conjunctivitis, macular degeneration, dry eye disease and other eye diseases increased significantly.
2022, the size of the ophthalmology market will exceed 100 billion data show that from 2013 to 2017, the size of China's ophthalmology market increased from 46.7 billion yuan to 86.6 billion yuan, with a compound annual growth rate of 16.7%.
With the increase in the incidence of ophthalmology, the upgrading of ophthalmology treatment technology, and the improvement of patient's awareness of diagnosis and treatment, the size of China's ophthalmology market is expected to continue to grow at a growth rate of about 14% between 2018 and 2022, with a total size expected to exceed 100 billion yuan.
it is understood that due to the particularity of the eye structure, systemic drug delivery can not reach the eye lesions department in a timely and effective manner, only when the infection is more serious use of systemic medication.
therefore, the treatment of ophthalmological diseases, especially eye watch diseases, generally use local treatment methods, mainly eye drops, ointments, injections, gels, eye cavity application drugs.
note that although there are a wide variety of drugs, ophthalmology drugs have long been difficult to come up with large varieties of the argument.
but this has begun to change after the emergence of anti-vascular endotrophic growth factor (anti-VEGF) under-eye injection drugs.
that Abersip's global sales in 2019 are close to the $10 billion mark, firmly in the top 10 of prescription drug sales, and there is still room for growth.
experts believe that in the face of such a huge market, coupled with the momentum of sustained growth, the ophthalmology market will become one of the more prominent segments of the pharmaceutical industry.
addition, as the market continues to grow, it will also become a gold track for many pharmaceutical companies.
China's ophthalmology drug market, the rise of domestic pharmaceutical companies in fact, in China's ophthalmology drug market, foreign enterprises with strong technical strength and strong brand promotion efforts are firmly occupying the leading position in the ophthalmology drug hospital market.
, Japan, Novarce, the United States, such as foreign pharmaceutical giants are continuing to add code to the domestic ophthalmology drug market.
Today, in May this year, the high-speed filling line of Sakeng Pharmaceuticals (China) was officially put into commercial production, directly increasing the existing production speed by nearly six times, allowing the Suzhou plant's production capacity to triple in a short period of time.
addition, Sant'an is also building a new plant with a construction area of 120,000 square meters and an annual production capacity of 1 billion pharmaceuticals in Suzhou Industrial Park.
, in the face of such a huge ophthalmology market, local eye medicine companies will not miss.
it is learned that the rapid rise of domestic ophthalmology drug companies, Kanghong Pharmaceuticals, All Life Pharmaceuticals, Xingqi Eye Medicine, Zhuhai Yisheng, etc. are in the research and development or the introduction of new drugs to add code card position.
that three ophthalmology companies have introduced new products in the past two weeks.
October 30, Ocon vision announced that it will conduct a clinical Phase III. phase III study of OT-702 (LY09004) Abersip biosimilars with Boan Biosimilars of Greenleavers Pharmaceuticals, and obtain the exclusive commercial rights of LY09004 in Chinese mainland; On October 19th, Zhaoke Ophthalmology, part of Lee's Pharmaceutical Company, announced that it had reached a product introduction agreement with Nevakar, which would cost up to $102 million to obtain the exclusive commercialization rights of low-concentration atropans in Greater China, South Korea and some Southeast Asian countries.
conclusion, in China's ophthalmology drug market, foreign enterprises with strong technical strength and strong brand promotion efforts still firmly occupy the leading position in the ophthalmology hospital market.
but with the rapid growth of the ophthalmology market, local eye drug companies are also beginning to rise.
future, in order to compete with multinational pharmaceutical companies in the eye drug market, domestic enterprises also need to rise to the fore and accelerate the pace of innovation and research and development.